Compare SRI & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRI | MCRB |
|---|---|---|
| Founded | 1965 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.9M | 162.7M |
| IPO Year | 1997 | 2015 |
| Metric | SRI | MCRB |
|---|---|---|
| Price | $5.81 | $17.19 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 1 | 3 |
| Target Price | ★ $16.00 | $14.33 |
| AVG Volume (30 Days) | 167.1K | ★ 323.3K |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.62 |
| Revenue | ★ $874,357,000.00 | $351,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.68 | N/A |
| P/E Ratio | ★ N/A | $28.23 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.54 | $6.53 |
| 52 Week High | $9.10 | $29.98 |
| Indicator | SRI | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 43.07 | 49.93 |
| Support Level | $5.54 | $16.61 |
| Resistance Level | $5.85 | $18.86 |
| Average True Range (ATR) | 0.21 | 3.42 |
| MACD | 0.07 | -0.19 |
| Stochastic Oscillator | 84.31 | 11.70 |
Stoneridge Inc is a manufacturer of electrical and electronic components used in automotive vehicles. The company produces instrumentation systems, vehicle management electronics, application-specific switches and actuators, sensors, security alarms, and vehicle tracking devices and monitoring services for commercial, automotive, off-highway, and agricultural vehicle markets. The company has three reportable segments: Control Devices, Electronics, and Stoneridge Brazil. It generates the majority of its revenue from the Electronics segment that produces driver information systems, camera-based vision systems, connectivity, and compliance products, and electronic control units. Its geographic segments include America, South America, Europe and Other.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.